Patient-Specific Modeling of Diffuse Large B-Cell Lymphoma
Personalized medicine aims to tailor treatment to patients based on their individual genetic or molecular background. Especially in diseases with a large molecular heterogeneity, such as diffuse large B-cell lymphoma (DLBCL), personalized medicine has the potential to improve outcome and/or to reduc...
Saved in:
Main Authors: | Kirsten Thobe, Fabian Konrath, Björn Chapuy, Jana Wolf |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/fa11e8ee04db491da78735748c189709 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma
by: Kristin Stirm, et al.
Published: (2021) -
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells
by: Falgàs A, et al.
Published: (2021) -
Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis
by: Liping Fan, et al.
Published: (2021) -
Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
by: Dipenkumar Modi, et al.
Published: (2021) -
Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
by: Edit Porpaczy, et al.
Published: (2021)